WaveMan
WaveMan · Company
GSK · Gsk Plc
> Search tickers & screens ⌘K
LIVE
← All companies

GSK GSK (GSK) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001131399
Quote by TradingView
Congress · 1Form 144 · 1
Insider buyers, 180 days
0
Funds added, last quarter
495
13F, latest reported quarter

What the filings say about GSK

Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-10-31
Planned sales (Form 144), 90 days
$2.3M
1 notice

GSK insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for GSK plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
495 funds bought in last quarter
more than 98% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
below 83% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GSK

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns GSK: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
64,961,641 sh
$3.4B
Dodge & Cox
48,197,514 sh
$2.5B
Fisher Asset Management, LLC
35,722,792 sh
$1.9B
PRIMECAP MANAGEMENT CO/CA/
25,182,068 sh
$1.3B
WELLINGTON MANAGEMENT GROUP LLP
11,396,249 sh
$597.4M

Congress trades in GSK

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Lisa McClain
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Lisa McClain
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Valerie Hoyle
Sold 2025-09-23 · disclosed 17 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-08-04 · disclosed 39 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GSK planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Martinez Maria E
Filed 2026-08-20
$2.3M

GSK mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Pharmaceuticals Portfolio
$122.6M position · as of 2026-05-31
8.2%
VanEck Pharmaceutical ETF
$38.9M position · as of 2026-06-30
4.4%
ICON EQUITY INCOME FUND
$1.7M position · as of 2026-06-30
3.9%
Callodine Equity Income Series
$8.9M position · as of 2026-06-30
3.8%
Huber Mid Cap Value Fund
$480.7K position · as of 2026-07-31
3.8%
Keating Active ETF
$4.4M position · as of 2026-07-31
3.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 495 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $2.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GSK financials

Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Gross profit$23.6B$22.3B$21.8B$19.8B
Net income$6.3B$3.0B$5.3B$15.6B
SEC XBRL, fiscal years, as known on 2026-10-27

GSK Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
66
Inputs
  • Funds adding, latest quarter495 · 98 pct, sector of 698
  • Congress net buyers, 365d0 · 33 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
83
Inputs
  • Short interest, % of float+0.8% · 83 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GSK filings, in plain words

Have members of Congress traded GSK?

Yes. In the year to 2026-10-27, 1 House member disclosed buying GSK and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.

Are there planned insider sales of GSK?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $2.3M of stock; the latest, by Martinez Maria E, was filed 2026-08-20.

Read the full summary

In the year to 2026-10-27, 1 member of Congress disclosed buying GSK and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $2.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies